Zsófia Miltényi

Zsófia Miltényi

Auto-generated profile, based on publicly available information

Zsófia Miltényi

A Department of Hematology , Institute for Internal Medicine, Faculty of Medicine, University of Debrecen , Debrecen , Hungary

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 December 2014 in Expert Opinion on Drug Metabolism & Toxicology
Verified
Journal Article
Closed access
ÁIÁrpád Illés
Árpád Illés
ÁJÁdám Jóna
Ádám Jóna
ZMZsófia Miltényi
Zsófia Miltényi
Hodgkin's lymphoma (HL) is a highly curable lymphoma with a 70 - 90% long-term survival; however, patients with relapsed or refractory disease may need additonal therapies and have significantly worse prognosis. Brentuximab vedotin (BV) is an anti-CD-30 antibody-drug conjugate, which was approved for treating classical HL patients following autologous stem cell transplantation or failure of at least two prior multi-agent chemotherapies within a year. Current clinical trials are investigating the role of BV in frontline, salvage and adjuvant setting of treatment. Safety and efficacy results of completed trials are summarized in this review. Metabolic, pharmacokinetic issues of BV are also discussed. BV is a targeted therapeutic option for treating HL, which is a significant improvement compared to conventional multiagent chemotherapy. It may represent a valid option for heavily pretreated patients. Currently running clinical trials are seeking a role for BV in the first-line setting, as well as treating autologous stem cell transplant candidate patients, relapsing after autologous stem cell transplant, bridging to allogenic stem cell transplant and treating elderly patients. Indication of drug may change, expand and an exact role may be established in the upcoming 5 years based on the results of currently running trials.

1 January 2012 in Journal of Hematology
Verified
Journal Article
Open access
PDF file
PAPayer
Payer
EPEdit Payer
Edit Payer
ZMZsofia Miltenyi
Zsofia Miltenyi
ZSZsofia Simon
Zsofia Simon
FMFerenc Magyari
Ferenc Magyari
AIArpad Illes
Arpad Illes
Diffuse large B-cell lymphoma arising from multicentric Castleman disease is an aggressive disorder with short survival. In 2001 our 46-year old patient presented cervical lymphadenopathy. The third bioptic sample proved HHV8 positive Castleman disease in 2002. Chemoterapy (steroid, cyclophosphamide, CVP, interferon-α, thalidomide) and radiotherapy was given with themporary success. In 2009 compression of the respiratory tract needed mantle irradiation, and rapid progression developed, inguinal biopsy revealed DLBCL. R-CHOP was started, but the interim PET/CT showed no respons, thus therapy was changed to R-DHAP, autologous stem cell transplantation was planned. The stem cell collection was made after 2 cycles of chemotherapy. However, further progression could be detected which seemed to be chemoresistant (R-IGEV, R-ICE). Palliative irradiation was performed but serious myelosuppression was developed which led to febrile neutropenia with pneumonia and sepsis. Despite of targeted antibiotic treatment the infection caused our patient’s death six months after the diagnosis of DLBCL. We would like to highlite the importance of the repeated biopsies if the behavior of a disease has changed and the rare disorders needed personalised treatment.doi:10.4021/jh27w

16 February 2016 in Hematology
Verified
Journal Article
Closed access
FMFerenc Magyari
Ferenc Magyari
SBSándor Barna
Sándor Barna
KHKata Husi
Kata Husi
ZSZsófia Simon
Zsófia Simon
ZMZsófia Miltényi
Zsófia Miltényi
ÁIÁrpád Illés
Árpád Illés
Objective and importance: Hodgkin's lymphoma (HL) is a well-curable disease. The treatment usually includes combined multiagent conventional chemotherapy and radiotherapy. One-fifth of the patients need repeated treatments because of relapse or primary progressive disease. Those HL patients, who cannot be cured at least with salvage therapy (including autologous haemopoietic stem cell transplantation (auto-HSCT)), have really unfavourable prognosis. Intervention: For this heavily pretreated subset of HL patients, novel but less toxic treatment strategies should be considered. Brentuximab-vedotin (BV) is a novel targeted treatment option, which was administered after the failure of two different regimens in patients, who were ineligible for auto-HSCT or after the failure of auto-HSCT. Moreover, there are favourable data with chemotherapeutical regimens supplemented with rituximab not only in relapsed but also in newly diagnosed classical HL patients. Bendamustine, an almost forgotten 50-year-old drug, lives its renaissance in the twenty-first century, which can be administered in refractory HL as well. Combination of the ‘new’ and ‘old’ drugs might be also helpful. Conclusion: Our data suggest that rituximab plus bendamustine (supplemented with or without BV) could be a suitable alternative bridging salvage therapy for heavily pretreated HL patients.

6 October 2002
Verified
Journal Article
Closed access
KKKatalin Keresztes
Katalin Keresztes
ZMZsófia Miltényi
Zsófia Miltényi
CACsilla András
Csilla András
AIArpád Illés
Arpád Illés

6 March 2006
Verified
Journal Article
Closed access
ZMZsófia Miltényi
Zsófia Miltényi
GSGyörgy Székely
György Székely
ZSZsófia Simon
Zsófia Simon
KKKatalin Keresztes
Katalin Keresztes
AIArpád Illés
Arpád Illés

1 January 2002
Verified
Journal Article
Closed access
AIArpád Illés
Arpád Illés
LGLajos Gergely
Lajos Gergely
ZMZsófia Miltényi
Zsófia Miltényi
KKKatalin Keresztes
Katalin Keresztes
SOSándor Olvasztó
Sándor Olvasztó
KDKatalin Dankó
Katalin Dankó